Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals (ZNTL) recorded zero cyber incidents and zero red-flag 8-K filings over the past 90 days, reflecting a stable recent operational window. However, a quiet recent period does not eliminate underlying risks; the 90-day snapshot misses material events and structural vulnerabilities that emerge over longer time horizons. The full $49 Report extends analysis to 12 months of filing history, calculates dilution risk scores from equity financing patterns, contextualizes all material 8-K events, and surfaces AI-detected risk signals in clinical, regulatory, and market positioning. The full $49 Report adds comprehensive dilution analysis, 12-month event context, and forward-looking risk scoring.